The case for widening the #intravesical approach to #bladder diseases and disorders In the European Association of #Urology 2024 conference, intravesical chemotherapy “took centre stage:” https://www.linkedin.com/pulse/eau24-expert-commentary-professor-fufu-zheng-nmibc-postoperative-i6xre?trk=organization_guest_main-feed-card_feed-article-content The case for their use in uro-oncology was made over 60 years ago with the introduction of Mitiomycin C. The value in delivering d

From our CMO Professor Scott Glickman Colleagues: In medical and surgical services spanning primary through intensive care, we are dogged by UTI with their acute and long-term complications: treatment failures, recurrences, urosepsis, antimicrobial resistance (AMR) and high costs. Despite continuous improvements in antibiotic stewardship, these problems show little sign of abating. Something else must be involved. Antibiotic overuse and misuse shouldn’t be blamed exclusively